| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Alessia Luoni, Fabio Fumagalli, Giorgio Racagni, Marco A Riv. Repeated aripiprazole treatment regulates Bdnf, Arc and Npas4 expression under basal condition as well as after an acute swim stress in the rat brain. Pharmacological research. vol 80. 2015-01-06. PMID:24309096. |
on these bases, the major accomplishment of this work was to investigate neuroadaptive changes set in motion by repeated treatment with aripiprazole, a novel apd that is unique for being a partial agonist at dopamine d2 receptors. |
2015-01-06 |
2023-08-12 |
rat |
| Gayatri Saraf, Rishikesh V Behere, Ganesan Venkatasubramanian, Naren P Rao, Shivarama Varambally, B N Gangadha. Hyperprolactinemia with aripiprazole: understanding the paradox. American journal of therapeutics. vol 21. issue 3. 2014-12-24. PMID:22357167. |
this partial d2 agonistic activity of aripiprazole could be dose related, and hence, at higher doses, aripiprazole by itself can have dopamine antagonistic properties and hence cause prolactin system abnormalities. |
2014-12-24 |
2023-08-12 |
Not clear |
| Eiji Kirin. Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents. Adolescent health, medicine and therapeutics. vol 5. 2014-12-04. PMID:25473324. |
aripiprazole acts as a serotonin 5-ht2a receptor antagonist, as well as a partial agonist of the serotonin 5-ht1a and dopamine d2 receptors. |
2014-12-04 |
2023-08-13 |
Not clear |
| Rudy Schreiber, Adrian Newman-Tancred. Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT(1A) receptor activation. Neurobiology of learning and memory. vol 110. 2014-12-03. PMID:24423786. |
recent antipsychotics, including clozapine and aripiprazole, exhibit different levels of 5-ht(1a) receptor partial agonism and may, therefore, differentially elicit hippocampal adult neurogenesis and increases in prefrontal cortex dopamine. |
2014-12-03 |
2023-08-12 |
Not clear |
| Fausto A Varela, Taleen Der-Ghazarian, Ryan J Lee, Sergios Charntikov, Cynthia A Crawford, Sanders A McDougal. Repeated aripiprazole treatment causes dopamine D2 receptor up-regulation and dopamine supersensitivity in young rats. Journal of psychopharmacology (Oxford, England). vol 28. issue 4. 2014-11-24. PMID:24045880. |
repeated aripiprazole treatment causes dopamine d2 receptor up-regulation and dopamine supersensitivity in young rats. |
2014-11-24 |
2023-08-12 |
human |
| Charles R Conway, John T Chibnall, Paul Cumming, Mark A Mintun, Marie Anne I Gebara, Dana C Perantie, Joseph L Price, Martha E Cornell, Jonathan E McConathy, Sunil Gangwani, Yvette I Shelin. Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: a preliminary PET study. Psychiatry research. vol 221. issue 3. 2014-11-02. PMID:24468015. |
in vivo animal studies and in vitro human studies using cloned dopamine dopamine d2 receptors suggest aripiprazole is a partial dopamine agonist; in this preliminary neuroimaging trial, we hypothesized that aripiprazole's antidepressant augmentation efficacy arises from dopamine partial agonist activity. |
2014-11-02 |
2023-08-12 |
human |
| D Holthoewer, K M Kirschbaum, J Frisch, C Hiemke, U Schmit. Pharmacodynamic effects of aripiprazole and ziprasidone with respect to p-glycoprotein substrate properties. Pharmacopsychiatry. vol 46. issue 5. 2014-10-06. PMID:23737243. |
aripiprazole, an atypical antipsychotic drug with mixed antagonism and agonism on dopamine d2 and serotonin receptors, is a substrate of the efflux transporter p-glycoprotein (p-gp). |
2014-10-06 |
2023-08-12 |
mouse |
| Ken Inada, Hidehiro Oshibuchi, Jun Shigook. [Significance of the pharmacotherapy of schizophrenia in the emotional context processing of cognition]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology. vol 33. issue 3. 2014-09-25. PMID:25069242. |
antipsychotic drugs, such as haloperidol, aripiprazole, and clozapine, suppress this increased release of dopamine in the amygdala in response to conditioned stimuli. |
2014-09-25 |
2023-08-13 |
rat |
| L Gaboriau, C Victorri-Vigneau, M Gérardin, G Allain-Veyrac, P Jolliet-Evin, M Grall-Bronne. Aripiprazole: a new risk factor for pathological gambling? A report of 8 case reports. Addictive behaviors. vol 39. issue 3. 2014-09-15. PMID:24315783. |
another dopamine agonist, aripiprazole, could be a new risk factor. |
2014-09-15 |
2023-08-12 |
Not clear |
| Wei-Ting Liao, Ya-Mei Ba. Major depressive disorder induced by prolactinoma--a case report. General hospital psychiatry. vol 36. issue 1. 2014-09-01. PMID:24182617. |
after a dopamine agonist (dostinex) and aripiprazole were prescribed, the patient's depressed mood remitted and her menstruation normalized. |
2014-09-01 |
2023-08-12 |
Not clear |
| Yoshihiro Seki, Takahiro A Kato, Akira Monji, Yoshito Mizoguchi, Hideki Horikawa, Mina Sato-Kasai, Daigo Yoshiga, Shigenobu Kanb. Pretreatment of aripiprazole and minocycline, but not haloperidol, suppresses oligodendrocyte damage from interferon-γ-stimulated microglia in co-culture model. Schizophrenia research. vol 151. issue 1-3. 2014-07-29. PMID:24100191. |
we have reported that not only atypical antipsychotics with dopamine d2 receptor (d2r) antagonism but also aripiprazole, a unique antipsychotic drug with d2r partial agonism, inhibit microglial activation in vitro. |
2014-07-29 |
2023-08-12 |
Not clear |
| Cristiano Termine, Claudia Selvini, Giorgio Rossi, Umberto Balotti. Emerging treatment strategies in Tourette syndrome: what's in the pipeline? International review of neurobiology. vol 112. 2014-07-14. PMID:24295630. |
the most commonly prescribed drugs are dopamine antagonists, such as typical (e.g., haloperidol, pimozide) and atypical neuroleptics (e.g., risperidone, aripiprazole), and α-2-adrenoreceptor agonists (e.g., clonidine). |
2014-07-14 |
2023-08-12 |
Not clear |
| Gian Marco Leggio, Salvatore Salomone, Claudio Bucolo, Chiara Platania, Vincenzo Micale, Filippo Caraci, Filippo Drag. Dopamine D(3) receptor as a new pharmacological target for the treatment of depression. European journal of pharmacology. vol 719. issue 1-3. 2014-07-02. PMID:23872400. |
a number of experimental drugs in pre-clinical or clinical development, including aripiprazole and cariprazine, may act as antidepressants because of their partial agonist activity at dopamine d3 receptors. |
2014-07-02 |
2023-08-12 |
Not clear |
| S K Sha. A comparative study of sexual dysfunction in schizophrenia patients taking aripiprazole versus risperidone. Kathmandu University medical journal (KUMJ). vol 11. issue 42. 2014-06-23. PMID:24096218. |
newer antipsychotic aripiprazole, partial dopamine agonist, with neutral effect on prolactin level or even decreasing it, is associated with avoidance of sexual dysfunction. |
2014-06-23 |
2023-08-12 |
Not clear |
| Deanna L Kelly, Heidi J Wehring, Amber K Earl, Kelli M Sullivan, Faith B Dickerson, Stephanie Feldman, Robert P McMahon, Robert W Buchanan, Dale Warfel, William R Keller, Bernard A Fischer, Joo-Cheol Shi. Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin). BMC psychiatry. vol 13. 2014-05-08. PMID:23968123. |
treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing daamsel clinical trial (dopamine partial agonist, aripiprazole, for the management of symptomatic elevated prolactin). |
2014-05-08 |
2023-08-12 |
Not clear |
| Tien-Yu Chen, Nian-Sheng Tzen. Aripiprazole: a dopamine modulator that mimics methylphenidate in producing faster antidepressant effects. Medical hypotheses. vol 81. issue 2. 2014-02-03. PMID:23751312. |
aripiprazole: a dopamine modulator that mimics methylphenidate in producing faster antidepressant effects. |
2014-02-03 |
2023-08-12 |
Not clear |
| Tien-Yu Chen, Nian-Sheng Tzen. Aripiprazole: a dopamine modulator that mimics methylphenidate in producing faster antidepressant effects. Medical hypotheses. vol 81. issue 2. 2014-02-03. PMID:23751312. |
we hypothesize that a low dose of aripiprazole might play a role as a dopamine agonist similar to that of methylphenidate due to its partial dopamine d2 agonist and 30% intrinsic dopaminergic activity. |
2014-02-03 |
2023-08-12 |
Not clear |
| Mahima Panigrahi, Susanta Kumar Padhy, Rajesh Rath. Aripiprazole monotherapy in an adolescent worsens psychosis. Indian journal of pharmacology. vol 45. issue 2. 2014-01-23. PMID:23716902. |
aripiprazole, a partial agonist of dopamine and a second generation antipsychotic, has been approved specifically for treatment of children with schizophrenia of aged 13-17 years. |
2014-01-23 |
2023-08-12 |
Not clear |
| Ramakrishna Nirogi, Vishwottam Kandikere, Pradeep Jayarajan, Gopinadh Bhyrapuneni, Ramanatha Saralaya, Nageswararao Muddana, Renny Abraha. Aripiprazole in an animal model of chronic alcohol consumption and dopamine D₂ receptor occupancy in rats. The American journal of drug and alcohol abuse. vol 39. issue 2. 2014-01-17. PMID:23421566. |
aripiprazole in an animal model of chronic alcohol consumption and dopamine d₂ receptor occupancy in rats. |
2014-01-17 |
2023-08-12 |
rat |
| Leslie Citrom. Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy. Advances in therapy. vol 30. issue 2. 2013-12-17. PMID:23361832. |
cariprazine differs from aripiprazole in terms of dopamine d3 receptor selectivity. |
2013-12-17 |
2023-08-12 |
Not clear |